SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
Active, not recruiting · NCT06149793 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Infant, Newborn, Diseases, cystic fibrosis, cystic fibrosis-related diabetes, hereditary disease, lung disorder, pancreas disorder, respiratory system disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-09-21 | NCT06149793 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| University of Minnesota | 344 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| University of Minnesota | Minneapolis | United States | 325 |